loading page

Prescribing direct-acting oral anticoagulants---mind the evidence gap
  • +2
  • Elizabeth Adeyeye,
  • Carmela Maniero,
  • Emma Magavern,
  • Robin Ferner,
  • Patricia McGettigan
Elizabeth Adeyeye
Barts Health NHS Trust

Corresponding Author:[email protected]

Author Profile
Carmela Maniero
William Harvey Research Institute
Author Profile
Emma Magavern
William Harvey Research Institute
Author Profile
Robin Ferner
Birmingham City Hospital
Author Profile
Patricia McGettigan
William Harvey Research Institute
Author Profile


Direct-acting oral anticoagulants (DOACs) are licensed for the prevention of thromboembolism in non-valvular atrial fibrillation amongst other indications. Prescribers use information derived from the summary of product characteristics which is based on the key trials supporting the DOAC’s market authorisation. However, prescribers may be aware of the limitations of these trials regarding underrepresentation of patient populations commonly encountered in clinical practice and how this may adversely impact them. This review highlights the gaps in the licensing evidence using 3 clinical vignettes that explore prescribing challenges in the elderly, obese and female patients.
28 Mar 2022Submitted to British Journal of Clinical Pharmacology
29 Mar 2022Submission Checks Completed
29 Mar 2022Assigned to Editor
06 Apr 2022Reviewer(s) Assigned
16 May 2022Review(s) Completed, Editorial Evaluation Pending
16 May 2022Editorial Decision: Revise Minor
11 Jun 20221st Revision Received
17 Jun 2022Submission Checks Completed
17 Jun 2022Assigned to Editor
17 Jun 2022Review(s) Completed, Editorial Evaluation Pending
20 Jun 2022Editorial Decision: Accept
13 Jul 2022Published in British Journal of Clinical Pharmacology. 10.1111/bcp.15450